Metastatic uveal melanoma has historically seen low research investment, limited randomized clinical trials, and few FDA-approved therapies. Progress in this rare, biologically distinct disease requires continued dedication and innovative solutions that target the key drivers of uveal melanoma and advance disease management.1-6

Laboratory professional representing scientific commitment to advancing uveal melanoma care

Sign up for the latest uveal melanoma and metastatic uveal melanoma treatment updates

Sign up for updates
Hand holding a smartphone displaying information about metastatic uveal melanoma advances

FDA, Food and Drug Administration.

1. Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743. doi:10.1101/gad.296962.117

2. Koch EAT, Heppt MV, Berking C. The current state of systemic therapy of metastatic uveal melanoma. Am J Clin Dermatol. 2024;25(5):691-700. doi:10.1007/s40257-024-00872-1

3. Hanratty K, Finegan G, Rochfort KD, Kennedy S. Current treatment of uveal melanoma. Cancers (Basel). 2025;17(9):1403. doi:10.3390/cancers17091403

4. Ziogas DC, Foteinou D, Theocharopoulos C, et al. State‑of‑the‑art in metastatic uveal melanoma treatment: a 2025 update. Curr Oncol Rep. 2025;27(7):803-821.
 doi:10.1007/s11912-025-01684-0

5. Mallone F, Sacchetti M, Lambiase A, Moramarco A. Molecular insights and emerging strategies for treatment of metastatic uveal melanoma. Cancers (Basel). 2020;12(10):2761. doi:10.3390/cancers12102761

6. Ng CA, Luckett T, Mulhern B, Kee D, Lai-Kwon J, Joshua AM. What matters most to people with metastatic uveal melanoma? a qualitative study to inform future measurement of health-related quality of life. Melanoma Res. 2024;34(3):248-257. doi:10.1097/CMR.0000000000000961